Pediatric Transplantation: Opportunities for Pharmacogenomics and Genomics

• Kirk R , DipchandAI, EdwardsLB et al. The Registry of the International Society for Heart and Lung Transplantation: Fifteenth Pediatric Heart Transplantation Report – 2012. J. Heart Lung Transplant. 31(10) , 1065–1072 (2012).
   PubMedGoogle Scholar
• Stehlik J , EdwardsLB, KucheryavayaAY et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report – 2011. J. Heart Lung Transplant. 30(10) , 1078–1094 (2011).
   PubMedGoogle Scholar
• Rieder M . New ways to detect adverse drug reactions in pediatrics. Pediatr. Clin. N. Am.59(5) , 1071–1092 (2012).
   PubMed Web of Science ®Google Scholar
• MacPhee IA , FredericksS, TaiT et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. 4(6) , 914–919 (2004).
   PubMed Web of Science ®Google Scholar
• Undre NA , van Hooff J, Christiaans M et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant. Proc.31(1–2) , 296–298 (1999).
   PubMed Web of Science ®Google Scholar
• Kausman JY , PatelB, MarksSD. Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients. Pediatr. Transplant.12(3) , 329–335 (2008).
   PubMed Web of Science ®Google Scholar
• Naesens M , SalvatierraO, LiL, KambhamN, ConcepcionW, SarwalM. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. Transplantation85(8) , 1139–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao W , FakhouryM, Jacqz-AigrainE. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Ther. Drug Monit.32(6) , 688–699 (2010).
   PubMed Web of Science ®Google Scholar
• Christians U , JacobsenW, BenetLZ, LampenA. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet.41(11) , 813–815 (2002).
   PubMed Web of Science ®Google Scholar
• Goto M , MasudaS, KiuchiT et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics14(7) , 471–478 (2004).
   PubMedGoogle Scholar
• Haufroid V , WallemacqP, VanKerckhoveV et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am. J. Transplant.6(11) , 2706–2713 (2006).
   PubMed Web of Science ®Google Scholar
• Uesugi M , MasudaS, KatsuraT, OikeF, TakadaY, InuiK. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet. Genomics16(12) , 119–127 (2006).
   PubMedGoogle Scholar
• Zhao W , ElieV, RousseyG et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin. Pharmacol. Ther. 86(6) , 609–618 (2009).
   PubMed Web of Science ®Google Scholar
• MacPhee IA , FredericksS, TaiT et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. 4(6) , 914–919 (2004).
   PubMed Web of Science ®Google Scholar
• Thervet E , LoriotMA, BarbierS et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6) , 721–726 (2010).
   PubMed Web of Science ®Google Scholar
• Gijsen V , MitalS, van Schaik RH et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J. Heart Lung Transplant.30(12) , 1352–1359 (2011).
   PubMed Web of Science ®Google Scholar
• Fanta S , NiemiM, JonssonS et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet. Genomics 18(2) , 77–90 (2008).
   PubMed Web of Science ®Google Scholar
• Ferraresso M , TuroloS, BelinghieriM et al. The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney tranpslant recipients. Pediatr. Transplant. 16 , 656–663 (2012).
   Web of Science ®Google Scholar
• Zhao W , FakhouryM, DeschenesG et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J. Clin. Pharmacol. 50(11) , 1280–1291 (2010).
   PubMed Web of Science ®Google Scholar
• Kirk R , EdwardsL, AuroraP et al. The Registry of the International Society for Heart and Lung Transplantation: Twelfth Pediatric Heart Transplantation Report – 2009. J. Heart Lung Transplant. 29(10) , 970–979 (2009).
   Google Scholar
• Roche SL , KaufmannJ, DipchandAI, KantorPF. Hypertension after pediatric heart transplantation is primarily associated with immunosuppressive regimen. J. Heart Lung Transplant.27(5) , 501–507 (2008).
   PubMed Web of Science ®Google Scholar
• Roche SL , O‘SullivanJJ, KantorPF. Hypertension after pediatric cardiac transplantation: detection, etiology, implications and management. Pediatr. Transplant.14(2) , 159–168 (2010).
   PubMed Web of Science ®Google Scholar
• Brozena S , JohnsonM, VenturaH et al. Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation: results of a prospective, randomized multicenter trial. JACC 27(7) , 1707–1712 (1996).
   Google Scholar
• Seeman T , SimkovaE, KreisingerJ et al. Control of hypertension in children after renal transplantation. Pediatr. Transplant. 10(3) , 316–322 (2006).
   PubMed Web of Science ®Google Scholar
• Ehret GB , MunroePB, RiceKM et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478(7367) , 103–109 (2011).
   PubMed Web of Science ®Google Scholar
• Levy D , EhretGB, RiceK et al. Genome-wide association study of blood pressure and hypertension. Nat. Genet. 41(6) , 677–687 (2009).
   PubMed Web of Science ®Google Scholar
• Newton-Cheh C , JohnsonT, GatevaV et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat. Genet. 41(6) , 666–676 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson JA . Advancing management of hypertension through pharmacogenomics. Ann. Med.44(Suppl. 1) , S17–S22 (2012).
   PubMed Web of Science ®Google Scholar
• Bhatnagar V , GarciaEP, O‘ConnorDT et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African–American men and women with early hypertensive renal disease. Am. J. Nephrol.31(2) , 95–103 (2010).
   PubMed Web of Science ®Google Scholar
• Lynch AI , BoerwinkleE, DavisBR et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA 299(3) , 296–307 (2008).
   PubMed Web of Science ®Google Scholar
• Mahle WT , VincentRN, BergAM, KanterKR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J. Heart Lung Transplant.24(1) , 63–66 (2005).
   PubMed Web of Science ®Google Scholar
• Penson MG , FrickerFJ, ThompsonJR et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J. Heart Lung Transplant. 20(6) , 611–618 (2001).
   PubMed Web of Science ®Google Scholar
• Chin C , GambergP, MilllerJ et al. Efficacy and safety of atorvastatin after pediatric heart transplantation. J. Heart Lung Transplant. 21(11) , 1213–1217 (2002).
   PubMed Web of Science ®Google Scholar
• Seipelt IM , CrawfordSE, RodgersS et al. Hypercholesterolemia is common after pediatric heart translantation: initial experience with pravastatin. J. Heart Lung Transplant. 23(3) , 317–322 (2004).
   PubMed Web of Science ®Google Scholar
• Hedman M , NeuvonenPJ, HolmbergM et al. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regiment of triple immunosuppression. Clin. Pharmacol. Ther. 75(1) , 101–109 (2004).
   PubMed Web of Science ®Google Scholar
• Exper panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics128(Suppl. 5) , S213–S256 (2011).
   PubMed Web of Science ®Google Scholar
• Kwiterovich PO , GiddingSS. Universal screening of cholesterol in children. Clin. Cardiol.35(11) , 662–664 (2012).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE , SchaechterJ, CarrilloA et al. Can the consequences of univesal cholesterol screening during childhood prevent cardiovascular disease and thus reduce long-term health care costs? Pediatr. Endocrinol. Rev. 9(4) , 698–705 (2012).
   PubMedGoogle Scholar
• The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy – a genome wide study. N. Engl. J. Med.359(8) , 789–799 (2008).
   PubMed Web of Science ®Google Scholar
• Wagner J , LeederJS. Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children. Pediatr. Clin. N. Am.59(5) , 1017–1037 (2012).
   PubMed Web of Science ®Google Scholar
• Hedman M , AntikainenM, HolmbergC et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br. J. Clin. Pharmacol. 61(6) , 706–715 (2006).
   PubMed Web of Science ®Google Scholar
• Boso V , HerreroMJ, BeaS et al. Increased hospital stay and allograft disfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285. Drug Metab. Dispos. 41(2) , 480–487 (2013).
   PubMed Web of Science ®Google Scholar
• Zeevi A , LunzJG, ShapiroR et al. Emerging role of donor-specific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum. Immunol. 70(8) , 645–650 (2009).
   PubMed Web of Science ®Google Scholar
• Schonder KS , MazariegosGV, WeberRJ. Adverse effects of immunosuppression in pediatric solid organ transplantation. Pediatr. Drugs12(1) , 35–49 (2010).
   PubMedGoogle Scholar
• Taegtmeyer AB , BreenJB, RogersP et al. Effect of adenosine monophosphate deaminase-1 C34T allele on the requirement for donor inotropic support and on the incidence of early graft dysfunction after cardiac transplantation. Am. J. Cardiol. 103(10) , 1457–1462 (2009).
   PubMed Web of Science ®Google Scholar
• Auerbach SR , ManlhiotC, ReddyS et al. Recipient genotype is a predictor of allograft cytokine expression and outcomes after pediatric cardiac transplantation. J. Am. Coll. Cardiol. 53(20) , 1909–1917 (2009).
   PubMed Web of Science ®Google Scholar
• Daly KP , MarshallAC, VincentJA et al. Endomyocardial biopsy and selective coronary angiography are low-risk procedures in pediatric heart transplant recipients: results of a multicenter experience. J. Heart Lung Transplant. 31(4) , 398–409 (2010).
   Web of Science ®Google Scholar
• Mehta R , LeeKJ, ChaturvediR, BensonL. Complications of pediatric cardiac catheterization: a review in the current era. Catheter Cardiovasc. Interv.72 , 278–285 (2008).
   PubMed Web of Science ®Google Scholar
• Pham MX , TeutebergJJ, KfouryAG et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N. Engl. J. Med. 362(20) , 1890–1900 (2010).
   PubMed Web of Science ®Google Scholar
• Evans RW , WilliamsGE, BaronHM et al. The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am. J. Transplant. 5(6) , 1553–1558 (2005).
   PubMed Web of Science ®Google Scholar
• Mital S , BernsteinD, WebberS et al. Molecular testing for cardiac allograft rejection in children: a multicenter study. Circulation 112(17) , II–419 (A2037) (2005).
   Web of Science ®Google Scholar
• Snyder TM , KhushKK, ValantineHA, QuakeSR. Universal noninvasive detection of solid organ transplant rejection. Proc. Natl Acad. Sci. USA108(15) , 6229–6234 (2011).
   PubMed Web of Science ®Google Scholar
• Manickaraj AK , MitalS. Personalized medicine in pediatric cardiology: do little changes make a big difference? Curr. Opin. Pediatr.24(5) , 584–591 (2012).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Pharmacogenetic tacrolimus dosing after pediatric transplantation. http://clinicaltrials.gov/show/NCT01655563
   Google Scholar
• The Pharmacogenomics Knowledge Base. www.pharmgkb.org
   Google Scholar